Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions for the pharma, biopharma and life sciences industries, has significantly expanded its drug delivery system manufacturing capacity.

As part of its footprint optimization plan, the company recently added a state-of-the-art production space for drug delivery devices to its facility in Bad Oeynhausen, northern Germany. This initiative provides more than 2,500 square meters of advanced manufacturing capacity.

The multi-million investment includes installation of an ISO 8 cleanroom environment, fully equipped for injection molding and automated assembly operations. These upgrades enable the site to support both Stevanato Group’s device production and contract manufacturing services enhancing operational flexibility, scalability, and speed across the company’s drug delivery systems portfolio.

The enhanced Bad Oeynhausen facility plays a pivotal role in advancing the production of key portfolio devices, including the Aidaptus autoinjector and Alina pen injector platforms. By integrating the company’s core capabilities in glass primary packaging, analytical services, and equipment manufacturing, Stevanato Group aims to enable safe, effective, and patient-centric combination products tailored to customer requirements.

“This investment underscores our commitment to advancing self-injection technologies and supporting our customers in delivering better patient outcomes,” said Michele Monico, President of DDS and IVD Business Unit at Stevanato Group. “As demand for drug delivery devices accelerates and patient adoption continues to rise—driven by the need for more convenient, personalized treatment options—expanding our manufacturing capacity is a strategic step to ensure readiness, agility, and innovation across our value chain.”